ijms-logo

Journal Browser

Journal Browser

Novel Approaches for Topical or Transdermal Delivery of Large Molecules

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 3580

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutics, Florida Agricultural and Mechanical University, Tallahassee, FL 32307, USA
Interests: pharmaceutical development; pharmaceutics and pharmaceutical technology

E-Mail Website
Guest Editor
SAIC-Frederick, Frederick, MD 21702, USA
Interests: biopharmaceutics; pharmacometrics

Special Issue Information

Dear Colleagues, 

Topical/transdermal drug delivery is ideal for delivering many active pharmaceutical ingredients (APIs), including insulin and antibodies, because of its unique advantage of bypassing the first-pass metabolism and protection from enzyme degradation in the gastrointestinal tract. Although significant advances have been made in the field of topical/transdermal drug delivery, there are only a few products in the market approved by the FDA. Patients suffering from certain diseases, including diabetes and cancer, require a convenient dosage form instead of painful injections. Therefore, there is an urgent need to explore novel strategies for transdermal delivery of large molecules.

Dr. Arvind Bagde
Prof. Dr. Shawn D Spencer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • topical
  • insulin
  • proteins
  • antibodies
  • transdermal
  • microneedle

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1691 KiB  
Article
Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles
by Keegan Braz Gomes, Sharon Vijayanand, Priyal Bagwe, Ipshita Menon, Akanksha Kale, Smital Patil, Sang-Moo Kang, Mohammad N. Uddin and Martin J. D’Souza
Int. J. Mol. Sci. 2023, 24(13), 10612; https://doi.org/10.3390/ijms241310612 - 25 Jun 2023
Cited by 5 | Viewed by 3136
Abstract
This study focused on developing an influenza vaccine delivered in polymeric nanoparticles (NPs) using dissolving microneedles. We first formulated an influenza extracellular matrix protein 2 virus-like particle (M2e VLP)-loaded with poly(lactic-co-glycolic) acid (PLGA) nanoparticles, yielding M2e5x VLP PLGA NPs. The vaccine particles were [...] Read more.
This study focused on developing an influenza vaccine delivered in polymeric nanoparticles (NPs) using dissolving microneedles. We first formulated an influenza extracellular matrix protein 2 virus-like particle (M2e VLP)-loaded with poly(lactic-co-glycolic) acid (PLGA) nanoparticles, yielding M2e5x VLP PLGA NPs. The vaccine particles were characterized for their physical properties and in vitro immunogenicity. Next, the M2e5x VLP PLGA NPs, along with the adjuvant Alhydrogel® and monophosphoryl lipid A® (MPL-A®) PLGA NPs, were loaded into fast-dissolving microneedles. The vaccine microneedle patches were then evaluated in vivo in a murine model. The results from this study demonstrated that the vaccine nanoparticles effectively stimulated antigen-presenting cells in vitro resulting in enhanced autophagy, nitric oxide, and antigen presentation. In mice, the vaccine elicited M2e-specific antibodies in both serum and lung supernatants (post-challenge) and induced significant expression of CD4+ and CD8+ populations in the lymph nodes and spleens of immunized mice. Hence, this study demonstrated that polymeric particulates for antigen and adjuvant encapsulation, delivered using fast-dissolving microneedles, significantly enhanced the immunogenicity of a conserved influenza antigen. Full article
Show Figures

Figure 1

Back to TopTop